The latest announcement is out from Theratechnologies ( (TSE:TH) ).
Theratechnologies has received FDA approval for its Prior Approval Supplement to the supplemental biologics license application for EGRIFTA SV, allowing for unrestricted distribution of the product. This approval, along with the recent approval of a new formulation, EGRIFTA WR, marks a significant step in resolving supply uncertainties and enhancing the patient experience, potentially strengthening the company’s market position in the treatment of excess abdominal fat in adults with HIV and lipodystrophy.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies is showing some financial improvements and strategic partnerships that may support long-term growth. However, high leverage, profitability issues, and technical weaknesses pose significant investment risks. While recent corporate events and earnings call insights provide some positive outlook, the overall stock score remains cautious due to these underlying challenges.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care.
YTD Price Performance: -10.87%
Average Trading Volume: 1,085,410
Technical Sentiment Signal: Hold
Current Market Cap: $71.32M
See more data about TH stock on TipRanks’ Stock Analysis page.